Evolent Health, Inc. (NYSE:EVH) Shares Sold by Engaged Capital LLC

Engaged Capital LLC lessened its holdings in shares of Evolent Health, Inc. (NYSE:EVH) by 3.0% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 3,989,468 shares of the technology company’s stock after selling 121,990 shares during the period. Evolent Health makes up approximately 18.3% of Engaged Capital LLC’s holdings, making the stock its largest position. Engaged Capital LLC owned 3.43% of Evolent Health worth $112,822,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in EVH. Quarry LP acquired a new stake in Evolent Health during the 2nd quarter valued at $32,000. Covestor Ltd boosted its position in Evolent Health by 138.1% in the 3rd quarter. Covestor Ltd now owns 1,424 shares of the technology company’s stock valued at $40,000 after buying an additional 826 shares during the last quarter. GAMMA Investing LLC boosted its position in Evolent Health by 5,365.5% in the 3rd quarter. GAMMA Investing LLC now owns 1,585 shares of the technology company’s stock valued at $45,000 after buying an additional 1,556 shares during the last quarter. Canada Pension Plan Investment Board bought a new position in Evolent Health in the 2nd quarter valued at $61,000. Finally, Quest Partners LLC bought a new position in Evolent Health in the 2nd quarter valued at $87,000.

Analyst Ratings Changes

A number of research analysts have commented on EVH shares. JMP Securities decreased their price objective on Evolent Health from $34.00 to $31.00 and set a “market outperform” rating on the stock in a research report on Friday, August 9th. JPMorgan Chase & Co. reduced their price target on Evolent Health from $45.00 to $15.00 and set an “overweight” rating on the stock in a research report on Friday, November 22nd. Citigroup reduced their price target on Evolent Health from $33.00 to $21.00 and set a “buy” rating on the stock in a research report on Wednesday, November 13th. KeyCorp initiated coverage on Evolent Health in a research report on Friday, October 11th. They issued an “overweight” rating and a $35.00 price target on the stock. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $20.00 price target on shares of Evolent Health in a research report on Tuesday, November 12th. One investment analyst has rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $25.90.

Evolent Health Stock Performance

Evolent Health stock opened at $12.93 on Friday. Evolent Health, Inc. has a 52 week low of $11.17 and a 52 week high of $35.00. The company has a current ratio of 1.04, a quick ratio of 1.04 and a debt-to-equity ratio of 0.58. The stock has a 50-day simple moving average of $22.19 and a 200 day simple moving average of $23.49.

About Evolent Health

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.